Floatz logo

[18F]FPyQCP

Ovarian Carcinoma

Blue Earth DiagnosticsPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

244 Active assets in the Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Carboplatin
University of Washington
Phase 3BB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

[18F]FPyQCP is also rated in:

invasive lobular breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
41 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →